Review Submission to USTR by US industry bodies raises alarm

U.S. India Business Council (USIBC) in a submission to U.S. Trade Representatives (USTR) for the 2016 Special 301 Review has clearly stated “the Government of India has privately reassured it would not use Compulsory Licenses (CL) for commercial purposes.”; indicating that India’s patent office will be restrictive in granting licenses to domestic players to produce cheaper versions of patented drugs. USIBC has also said that they were “encouraged by the way things are trending” in the developments related to the Intellectual Property Rights (IPR) policy in the last one year in India.

Submissions to USTR for the 2016 Special 301 Review made by at least four industry bodies, the US Chamber of Commerce, Pharmaceutical Research and Manufacturers of America (PhRMA), USIBC and Alliance for Fair Trade with India (AFTI) said that a “positive” approach has been developed by the India government in regard to compulsory licensing.

Read full submission: 

US Chamber of Commerce’s Global Intellectual Property Centre

http://www.regulations.gov/#!documentDetail;D=USTR-2015-0022-0026

US- India Business Council

http://www.regulations.gov/#!documentDetail;D=USTR-2015-0022-0034

PhRMA

http://www.phrma.org/sites/default/files/pdf/PhRMA_2016_Special_301_Submission.pdf

This entry was posted in Compulsory Licensing, Uncategorized, USTR 301 report. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s